Effects of Renal Replacement Therapy on Renal Recovery after Acute Kidney Injury

Antoine G. Schneider  Sean M. Bagshaw
Division of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alta., Canada

Abstract
Recovery of kidney function following an episode of acute kidney injury (AKI) is now acknowledged as a vital patient-centered outcome with clear health economic implications. In approximately 5–8% of critically ill patients with more severe forms of AKI, support with renal replacement therapy (RRT) is provided. Recent data have suggested that rates of RRT utilization in AKI are increasing. Despite advances in our understanding of how best to prescribe acute RRT in critically ill patients with AKI, additional aspects remain uncertain, predisposing to suboptimal delivery and variation in practice. Importantly, if, when, how, and by what principles we apply acute RRT for AKI are all treatment decision-related factors that are modifiable and may interact with recovery of kidney function. Limited data, mostly from observational studies and secondary analyses, have explored the specific association between acute RRT and recovery. Available data are not able to clarify whether providing any RRT in otherwise eligible patients with AKI impacts recovery. They are also unable to inform whether the timing or circumstance under which RRT is started impacts recovery. No studies have evaluated whether there is an optimal time to start RRT to maximize the probability of recovery. Accumulated evidence, mostly derived from observational studies, suggests initial therapy in critically ill patients with AKI with continuous RRT, compared with intermittent modalities, improves the probability of recovery to dialysis independence. Evidence from high-quality randomized trials failed to show any association between delivered dose intensity of RRT and recovery. The use of biocompatible membranes for acute RRT may improve recovery in AKI; however, data are inconsistent. Limited data have evaluated the impact of membrane flux properties on recovery. Preliminary data have suggested that circuit anticoagulation with citrate, which results in a reduction in membrane-induced oxidative stress and leukocyte activation, may be associated with improved recovery; however, further corroborative data are needed. Additional evidence, ideally from randomized trials, is clearly needed to inform best practice in the delivery of acute RRT to optimize probability of recovery of kidney function for survivors of AKI.

Key Words
Acute kidney injury · Biocompatible membranes · Citrate anticoagulation · Renal replacement therapy

Targeting Recovery from Acute Kidney Injury: Round Table Conference at the 19th International Conference on Continuous Renal Replacement Therapies (Manchester Grand Hyatt, San Diego, Calif., USA, March 2–3, 2014).
Introduction

Acute kidney injury (AKI) is a rapidly increasing and widespread problem, in particular among hospitalized patients with acute illness [1]. Mortality associated with AKI is unacceptably high; however, largely through enhanced awareness [2], heightened monitoring [3], and improved processes of care [4], rates over the last decade have shown a modest decline [5]. This has naturally promoted a greater focus on the survivorship issues following an episode of AKI. Recovery of kidney function is increasingly recognized as an important short- and long-term patient-centered and health economic outcome.

Among those who survive their acute illness, recovery of kidney function may or may not occur [6]. The trajectory of kidney function may include complete recovery (i.e., a return to a level of function near premorbid levels), incomplete or partial recovery (i.e., a reduction in function relative to baseline but not requiring RRT), and non-recovery (i.e., dialysis dependence). Partial or incomplete recovery may herald the development of new chronic kidney disease (CKD) if persistent loss of kidney function is significant. Studies have shown that the risk of incident or worsening CKD and end-stage kidney disease (ESKD) is higher among patients with AKI (whether RRT was acutely received or not) compared with matched non-AKI controls, even among those who may have had complete recovery from AKI [7–9]. New or worsened CKD or acceleration toward ESKD are major morbid events with significant downstream implications, including increased cardiovascular event risk, reduced health-related quality of life, and greater use of health services [10].

Ascertaining granular data on kidney function short of RRT dependence among survivors of AKI has been challenging. Accordingly, the majority of clinical studies have defined kidney recovery by whether patients remain dialysis dependent or not at various time points (i.e., hospital discharge, or 90-day or 1-year follow-up). This definition is sensible given its obvious importance for patients and because such data are easily captured and associated with patient level morbidity and system level resource utilization, as aforementioned. In large observational cohort studies, the rates of dialysis dependence amongst survivors of critical illness complicated by AKI have ranged between 13 and 29% (generally assessed at the point of hospital discharge) [10–14]. Among studies with a longer-term follow-up, any episode of AKI, requiring RRT or not, appears to be associated with a severalfold higher risk for developing ESKD and dialysis dependence [11, 12, 14–17]. Despite the pragmatism of using dialysis dependence to define recovery after AKI, this definition fails to consider the important modifying impact of new or worsened CKD and ongoing evidence of kidney damage (i.e., albuminuria) that fall short of needing RRT [18–20].

In a large cohort utilizing data from the United States Department of Veterans Affairs with detailed monitoring of kidney function for a 6-year period following critical illness, AKI was associated with a 4- to 6-fold increase in the risk of developing stage 4 CKD [21]. These findings have been replicated in another large population-based cohort study [22] and summarized in a systematic review [23] showing an unequivocal association between an episode of AKI and development of CKD.

One of the challenges of the evaluation of long-term kidney recovery after AKI is the competing risk of death, recognizing the high mortality associated with critical illness complicated by AKI. In long-term surveillance of the critically ill patients enrolled in the Randomized Evaluation of Normal versus Augmented Levels of RRT (RENAI) study, those surviving to the 90-day follow-up were shown to be more likely to die within 1 year of the episode of AKI than develop ESKD requiring dialysis initiation [24].

In this brief review, we will specifically focus on how RRT-related factors may influence and modify kidney recovery following an episode of AKI.

Impact of RRT on Recovery

Impact of a Decision to Initiate RRT on Renal Recovery

In critically ill patients with more severe forms of AKI, supportive therapy with RRT is often provided [14]. Life-threatening complications such as severe hyperkalemia, refractory acidosis, and severe fluid overload resulting in respiratory failure associated with AKI can be readily corrected with RRT. In these circumstances, the need to provide RRT would appear unequivocal. However, for critically ill patients with severe AKI but who have not developed life-threatening complications, the optimal time and circumstances for starting RRT is uncertain. This has contributed to suboptimal quality of RRT delivery and a wide variation in practice across jurisdictions [25]. Some recent data have even suggested that RRT application could, in some situations, be deleterious and impair renal recovery [26, 27].

In a secondary analysis of the Stuivenberg Hospital Acute Renal Failure (SHARF) 4 study, the development of ESKD and dialysis dependence among survivors to...
hospital discharge was found to be more common among RRT-treated compared with those treated more conservatively (no RRT; 24% for RRT vs. 9% for no RRT) [27]. In this study, treatment allocation bias was not adequately adjusted for as RRT initiation was not standardized and left to the discretion of the treating clinician. This contributed to significant variation in the utilization of RRT and observed mortality across contributing sites. Similarly, a large multicenter French study utilizing a comprehensive clinical and administrative database evaluated the association between RRT utilization in AKI and outcome [26]. In multivariable-adjusted analysis, including propensity score matching for receipt of RRT, no differences in mortality were found between those with and without RRT. While the authors reported that 27.2% of RRT-treated survivors remained RRT dependent at discharge from the intensive care unit, there was no long-term ascertainment of whether further recovery occurred in these patients or description of whether non-RRT-treated patients progressed to ESKD. Both of these studies remain prone to bias and residual confounding, and neither offered explanations for why selected patients with AKI and a high risk for mortality did not receive RRT.

Additional studies have clearly shown that, in the absence of consensus guidelines for when to optimally initiate RRT, RRT-treated patients remain fundamentally different from non-RRT-treated patients, which largely precludes any inferences from data outside of randomized trials [28, 29]. This was evident in a recent secondary analysis of the Beginning and Ending Supportive Therapy for the Kidney (BEST-Kidney) study, a large international multicenter observational study of AKI [28]. In this analysis, the decision to provide RRT in severe AKI appeared largely predicated on treating clinicians’ expectation of benefit. In close to 50% of the cases, RRT was withheld because of limitations of support or advanced age, where no benefit from RRT was expected. At the other end of the spectrum, RRT was also not provided to patients who appeared likely to undergo spontaneous recovery, such as those with adequate urinary output. Similar findings were made in another cohort [29] where limitations of medical therapy and perception of imminent renal recovery were the main reasons for not providing RRT. Unfortunately, these data collectively do not offer a clear view of whether the provision of any RRT in critically ill patients with AKI modifies the short- and long-term recovery of kidney function.

### Impact of RRT Timing on Renal Recovery

There are limited data specifically evaluating the timing and circumstances of RRT initiation in AKI patients on recovery of kidney function. A recent systematic review focusing on RRT timing in critically ill patients with AKI suggested earlier RRT compared with late, delayed, or standard RRT was associated with a nonsignificant trend for improved recovery [odds ratio (OR) 0.62, 95% confidence interval (CI) 0.34–1.13; 7 studies; 1,953 patients] (fig. 1) [30]. However, the studies included in this pooled analysis had a high risk of bias due to issues of
study design, case mix, definitions for ‘timing’, and variation in outcome ascertainment. Few randomized trials have evaluated early versus later RRT initiation [30–32]. The only high-quality trial randomly allocated 106 mechanically ventilated patients with AKI to three strategies of RRT (early high volume, early low volume, or late low volume) [31]. The trial found no significant differences in mortality or recovery of kidney function between the treatment strategies. Moreover, only 1.6% of survivors remained RRT dependent, limiting any robust comparison of timing on recovery.

Fluid accumulation in critically ill patients, in particular those with AKI, has clearly been associated with increased mortality and may be treated with RRT [33–35]. Recently, a small retrospective cohort study suggested excess fluid accumulation prior to starting RRT in critically ill patients with AKI was associated with a reduced likelihood of recovery [36]. These data imply that fluid accumulation may represent an important trigger for when to start RRT. Moreover, RRT may be one important element in a spectrum of options to mitigate excess fluid accumulation and overload in critically ill patients, independent of AKI.

The timing and circumstances under which RRT is initiated is clearly modifiable; however, high-quality data showing their association with recovery are lacking. Randomized trials on this issue are fortunately ongoing [37].

**Impact of RRT Modality on Renal Recovery**

RRT can be provided as continuous (CRRT) or intermittent (IRRT) therapy. The first evidence to suggest there may be an important difference in the rate of recovery was derived from a randomized clinical trial (RCT) comparing CRRT and IRRT [38]. This study found on intention-to-treat analysis that a lower number of surviving CRRT-treated patients were discharged with residual kidney dysfunction compared with IRRT-treated patients (4 vs. 17%, respectively); however, baseline case mix differences between groups and treatment crossover present challenges for strong inferences.

Coherent with these data are several large cohort studies showing rates of recovery to dialysis independence are lower for critically ill patients initially treated with CRRT compared with IRRT (table 1) [12, 39–41]. While neither RENAL nor the Acute Renal Failure Trial Network Study (ATN) showed any survival or renal recovery differences with dose intensity of RRT, there were striking differences between the two trials with respect to dialysis dependence at 28 days (45.2% for ATN vs. 13.3% for RENAL) or at the end of follow-up (24.6% for ATN vs. 5.6% for RENAL). While a direct comparison of the treatment strategies used between the trials is obviously prone to bias and challenging, it does question whether, in part, the greater exposure to IRRT in ATN compared with exclusive treatment with CRRT in RENAL is a contributing factor [42]. Recently, a large population-based Canadian study of critically ill patients surviving to 90 days after an episode of AKI treated with RRT utilizing propensity matching for treatment allocation found initial treatment with CRRT compared with IRRT was associated with a significantly lower likelihood of ESKD and dialysis dependence both at 90 days (16 vs. 21%) and during the

<table>
<thead>
<tr>
<th>First author</th>
<th>Country</th>
<th>Enrollment</th>
<th>Design</th>
<th>Population</th>
<th>Recovery</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mehta [38]</td>
<td>USA</td>
<td>1991–1995</td>
<td>MC, RCT</td>
<td>Mixed ICU</td>
<td>sCr return to ≤177 μmol/l (2 mg/dl)</td>
<td>↑ complete recovery with CRRT</td>
</tr>
<tr>
<td>Bell [12]</td>
<td>Sweden</td>
<td>1995–2004</td>
<td>MC, RC</td>
<td>Mixed ICU</td>
<td>RRT free</td>
<td>↓ ESKD with CRRT (8 vs. 17%)</td>
</tr>
<tr>
<td>Uchino [40]</td>
<td>World</td>
<td>2000–2004</td>
<td>MC, PC</td>
<td>Mixed ICU</td>
<td>RRT free</td>
<td>↓ DD with CRRT (11 vs. 35%)</td>
</tr>
<tr>
<td>Jacka [54]</td>
<td>Canada</td>
<td>2004</td>
<td>SC, RC</td>
<td>Mixed ICU</td>
<td>RRT free</td>
<td>↓ DD with CRRT (17 vs. 64%)</td>
</tr>
<tr>
<td>Lin [39]</td>
<td>Taiwan</td>
<td>2002–2006</td>
<td>MC, PC</td>
<td>Surgical ICU</td>
<td>RRT free</td>
<td>↑ recovery with CRRT</td>
</tr>
<tr>
<td>Andrikos [56]</td>
<td>Greece</td>
<td>2008</td>
<td>MC, PC</td>
<td>Mixed ICU</td>
<td>RRT free</td>
<td>↓ DD with CRRT (15 vs. 25%)</td>
</tr>
<tr>
<td>Wald [41]</td>
<td>Canada</td>
<td>1996–2009</td>
<td>MC, RC</td>
<td>Mixed ICU</td>
<td>RRT free conditional on survival to 90 days</td>
<td>↓ ESKD with CRRT (16 vs. 26%)</td>
</tr>
</tbody>
</table>

SC = Single center; MC = multicenter; PC = prospective cohort; RC = retrospective cohort; sCr = serum creatinine; IHD = intermittent hemodialysis; ICU = intensive care unit; DD = dialysis dependence; RIFLE = Risk, Injury, Failure, Loss of Kidney Function and End-Stage Kidney Disease Classification.
long-term follow-up (21 vs. 27%). Observations from two large, high-quality randomized trials provide further insight into the impact of RRT modality on renal recovery [43, 44].

A recent systematic review identified 50 unique studies reporting the rate of dialysis dependence among more than 6,500 survivors of AKI who received RRT for AKI (not including the recent study by Wald et al. [41]) [45]. In a pooled analysis, including both observational studies and randomized trials, IRRT as initial treatment modality was associated with a 1.7 times greater risk for dialysis dependence when compared with initial treatment with CRRT (OR 1.73; 95% CI 1.35–1.68). This finding was robust across subgroups including those with CKD; however, it did not reach statistical significance when the analysis was restricted to RCTs (OR 1.73; 95% CI 0.73–1.68; n = 7). Available RCTs were generally small, of lower quality, and had relatively few events for pooled analysis. In addition, observational studies showed evidence of treatment selection bias with IRRT-treated patients having lower illness severity, greater hemodynamic stability, and greater rates of CKD at baseline. Collectively, these data imply that among critically ill patients with AKI treated with IRRT, the use of high-flux (F12) compared with low-flux (F6) biocompatible membranes showed no difference in the rates of survival and recovery of kidney function to dialysis independence [50].

Fewer data have focused specifically on the membrane flux properties and recovery of kidney function in AKI. In a small, randomized trial of 72 critically ill patients with AKI treated with IRRT, the use of high-flux (F12) compared with low-flux (F6) biocompatible membranes showed no difference in the rates of survival and recovery of kidney function to dialysis independence [50].

Impact of RRT Dose/Intensity on Renal Recovery

Although highly debated during the previous decade, the question of whether the delivered dose of RRT impacts survival among critically ill patients with AKI has largely been resolved following the publication of two high-quality RCTs [43, 44]. In addition to showing no difference in survival, neither study found evidence that the RRT dose/intensity delivered affected recovery to dialysis independence.

Impact of Membrane Type on Renal Recovery

Selected studies have suggested the biocompatibility of the filter membrane used for IRRT in patients with AKI may influence recovery of kidney function [46, 47]; however, these findings have not been universal or consistent [48, 49]. In a small controlled trial of 52 patients with AKI, RRT utilizing cuprophane membranes (bioincompatible) elicited greater activation of complement (serum C3a) and oxidative stress (leukotriene B4) when compared to RRT with polyacrylonitrile membranes (bio compatible) [47]. This activation and alternation in immune function was believed to contribute to delayed or reduced likelihood of recovery. Indeed, in this trial, the group receiving RRT with cuprophane membranes required more RRT sessions (301 vs. 222) and was more likely to remain dialysis dependent 3 weeks after its initiation (33 vs. 25%). Among those weaned from RRT, the cuprophane-treated group required a longer duration until recovery (22 vs. 15 days) and was less likely to have normalized serum creatinine levels at 3 months (66 vs. 88%). These findings were supported by another small randomized trial of 72 patients with AKI allocated to receive RRT with either a cuprophane or polymethylmethacrylate membrane [46]. Those receiving RRT with cuprophane membranes had lower adjusted rates of recovery to dialysis independence (37 vs. 62%, p = 0.04). Among those recovering, use of a cuprophane membrane was associated with longer duration of RRT support (17 vs. 5 sessions, p = 0.02). Additional randomized trials and a systematic review (10 studies, 1,100 patients) found no clinical or statistical differences in recovery to dialysis independence by membrane compatibility [48, 49].

Impact of Anticoagulation Type on Renal Recovery

There is a paucity of data evaluating the impact of the choice of the anticoagulation type on the course of AKI and recovery of kidney function. Studies have suggested that use of citrate as an anticoagulant may have added pleiotropic effects beyond regional anticoagulation of the extracorporeal circuit. One small, randomized trial in 20 critically ill patients receiving CRRT for AKI compared the effect of regional citrate and heparin anticoagulation on measures of systemic oxidative stress and inflammation [51]. Citrate reduced prefilter myeloperoxidase and interleukin-8 levels compared with heparin. While heparin was associated with a reduction in tumor necrosis factor-α, prefilter myeloperoxidase levels were significantly higher compared with citrate. Similarly, heparin has been shown to activate complement and induce neutrophil degranulation in the extracorporeal circuit to a greater extent when compared with citrate [52]. Whether these observations are also impacted by citrate being associated with longer filter survival and reduced episodes of bleeding and need for transfusion is plausible but remains uncertain [53].
Conclusion

Recovery of kidney function after AKI is a vital patient-centered outcome with downstream health service and economic implications. In critical care settings, severe AKI is commonly treated with RRT and its utilization appears to be expanding. Importantly, the broad principles for how RRT is provided (i.e., timing, dose, modality, circuit characteristics, and anticoagulation) to critically ill patients are all modifiable and hence susceptible to practice variation. This would imply that treatment applied within current best practice may improve quality of care and outcomes; however, there is a relative paucity of sufficiently high quality evidence investigating the association between RRT and recovery of kidney function among survivors of AKI. Available data suggest initial therapy with CRRT, and use of biocompatible membranes and citrate anticoagulation may have some benefit to improve recovery; however, if and when to provide RRT still needs better clarification, and further studies focusing on renal recovery as an outcome are urgently needed.

Acknowledgments

Dr. Bagshaw holds a Canada Research Chair in Critical Care Nephrology and is a Clinical Investigator supported by Alberta Innovates – Health Solutions.

References


